Inhibitory effect of IGF-I on type 2 nitric oxide synthase expression in Ins-1 cells and protection against activation-dependent apoptosis: Involvement of phosphatidylinositol 3-kinase

Diabetes

Volumn 49, Issue 2, 2000, Pages 209-217

  Castrillo, Antonio ^a   Bodelón, Oscar G ^a   Boscá, Lisardo ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME ACTIVATION; ENZYME ANALYSIS; GENETIC TRANSFECTION; INFLAMMATION; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033969128     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.2.209     Document Type: Article

References (55)

1. Hugl SR, White MF, Rhodes CJ: Insulin-like growth factor I (IGF-I)-stimulated pancreatic β-cell growth is glucose-dependent: synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem 273:17771-17779, 1998
2. Hill DJ, Petrik J, Arany E, McDonald TJ, Delovitch TL: Insulin-like growth factors prevent cytokine-mediated cell death in isolated islets of Langerhans from pre-diabetic non-obese diabetic mice. J Endocrinol 161:153-165, 1999
3. Mabley JG, Belin V, John N, Green IC: Insulin-like growth factor I reverses interleukin-1β inhibition of insulin secretion, induction of nitric oxide synthase and cytokine-mediated apoptosis in rat islets of Langerhans. FEBS Lett 417:235-238, 1997
4. Kulik G, Klippel A, Weber MJ: Antiapoptotic signalling by the insulin-like growth factor 1 receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17:1595-1606, 1907
5. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249-252, 1995
6. Myers MGJ, Grammer TC, Wang LM, Sun XJ, Pierce JH, Blenis J, White MF: Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6K signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 269:28783-28789, 1994
7. White MF, Kahn CR: The insulin signaling system. J Biol Chem 269:1-4, 1994
8. Sarbassov DD, Peterson CA: Insulin receptor substrate-1 and phosphatidylinositol 3-kinase regulate extracellular signal-regulated kinase-dependent and -independent signaling pathways during myogenic differentiation. Mol Endocrinol 12:1870-1878, 1998
9. Myers MGJ, Backer JM, Sun XJ, Shoelson S, Hu P, Schlessinger J, Yoakim M, Schaffhausen B, White MF: IRS-1 activates phosphatidylinositol 3′-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci U S A 89:10350-10354, 1992
10. Patti ME, Sun XJ, Bruening JC, Araki E, Lipes MA, White MF, Kahn CR: 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-dencient mice. J Biol Chem 270:24670-24673, 1995
11. 130.Crk complex. J Biol Chem 273:26149-26156, 1998
12. Toker A, Cantley LC: Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387:673-676, 1997
13. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD: P110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 94:4330-4335, 1997
14. Shepherd PR, Withers DJ, Siddle K: Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 333:471-490, 1998
15. Diaz-Guerra MJM, Castrillo A, Martin-Sanz P, Bosca L: Negative regulation by phospliatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J Immunol 162:6184-6190, 1999
16. Pahan K, Raymond JR, Singh I: Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide-or cytokine-stimulated C6 glial cells. J Biol Chem 274:7528-7536, 1999
17. Xie QW, Whisnant R, Nathan C: Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon γ and bacterial lipopolysaccharide. J Exp Med 177:1779-1784, 1993
18. Diaz-Guerra MJM, Velasco M, Martin-Sanz P, Bosca L: Evidence for common mechanisms in the transcriptional control of type II nitric oxide synthase in isolated hepatocytes: requirement of NF-κB activation after stimulation with bacterial cell wall products and phorbol esters. J Biol Chem 271:130114-30120, 1996
19. Spink J, Cohen J, Evans TJ: The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase: activation by nuclear factor-κB. J Biol Chem 270:29541-29547, 1995
20. Ghosh S, May MJ, Kopp EB: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260, 1998
21. Bosca L, Hortelano S: Mechanisms of nitric oxide-dependent apoptosis: involvement of mitochondrial mediators. Cell Signal 11:239-244, 1999
22. Gansauge S, Nussler AK, Beger HG, Gansauge F: Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ 9:611-617, 1998
23. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB: Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130:167-178, 1992
24. Velasco M, Diaz-Guerra MJ, Martin-Sanz P, Alvarez A, Bosca L: Rapid Up-regulation of IκBβ and abrogation of NF-κB activity in peritoneal macrophages stimulated with lipopolysaccharide. J Biol Chem 272:23025-23030, 1997
25. Genot E, Cleverley S, Henning S, Cantrell D: Multiple p21ras effector path ways regulate nuclear factor of activated T cells. EMBO J 15:3923-3933, 1996
26. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A, Troso T, Nathan C: Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256:225-228, 1992
27. 15N]nitrate in biological fluids. Anal Biochem 126:131-138, 1982
28. Hortelano S, López-Collazo A, Boscá L: Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol 126:1139-1146, 1999
29. Tsai SH, Lui-Shiau SY, Lin JK: Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br J Pharmacol 126:673-680, 1999
30. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M: A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 388:548-554, 1997
31. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A: IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 278:860-866, 1997
32. Bruning JC, Winnay J, Cheatham B, Kahn CR: Differential signaling by insulin receptor substrate 1 (IRS-1) and 1RS- 2 in IRS-1-deficient cells. Mol Cell Biol 17:1513-1521, 1997
33. Kaliman P, Canicio J, Shepherd PR, Beeton CA, Testar X, Palacin M, Zorzano A: Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression blocks differentiation of L6E9 muscle cells. Mol Endocrinol 12:66-77, 1998
34. Crawley JB, Williams IM, Mander T, Brennan FM, Foxwell BMJ: Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J Biol Chem 271:16357-16362, 1990
35. Green DR, Reed JC: Mitochondria and apoptosis. Science 281:1309-1312, 1998
36. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1120-1132, 1997
37. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G: Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281:2027-2031, 1998
38. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA: IL-1 produced and released endogenously within human islets inhibits β cell function. J Clin Invest 102:516-526, 1998
39. Rabinovitch A: An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 14:129-151, 1998
40. Heitmeier MR, Scarim AL, Corbett JA: Double-stranded RNA inhibits β-cell function and induces islet damage by stimulating β-cell production of nitric oxide. J Biol Chem 274:12531-12536, 1999
41. Laffranchi R, Spinas GA: Interferon-γ inhibits insulin release and induces cell death in the pancreatic β-cell line INS-1 independently of nitric oxide production. Exp Cell Res 237:217-222, 1997
42. Sjoholm A: Aspects of the involvement of interleukin-1 and nitric oxide in the pathogenesis of insulin-dependent diabetes mellitus. Cell Death Differ 5:461-468, 1998
43. Takamura T, Kato I, Kimura N, Nakazawa T, Yonekura H, Takasawa S, Okamoto H: Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic β cells develop insulin-dependent diabetes without insulitis. J Biol Chem 273:2493-2406, 1998
44. Eizirik DL, Pavlovic D: Is there a role for nitric oxide in β-cell dysfunction and damage in IDDM? Diabetes Metab Rev 13:293-307, 1997
45. Flodstrom M, Tyrberg B, Eizirik DL, Sandler S: Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 48:706-713, 1999
46. Guan Z, Buckman SY, Baier LD, Morrison AR: IGF-I and insulin amplify IL-1β-induced nitric oxide and prostaglandin biosynthesis. Am J Physiol 274:F673-F679, 1998
47. Scarim AL, Heitmeier MR, Corbett JA: Heat shock inhibits cytokine-induced nitric oxide synthase expression by rat and human islets. Endocrinology 139:5050-5057, 1998
48. Darville MI, Eizirik DL: Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells. Diabetologia 41:1101-1108, 1998
49. Diaz-Guerra MJM, Castrillo A, Martin-Sanz P, Bosca L: Negative regulation by protein tyrosine phosphatase of IFN-γ-dependent expression of inducible nitric oxide synthase. J Immunol 162:6776-6783, 1999
50. Kim B, Cheng HL, Margolis B, Feldman EL: Insulin receptor substrate 2 and She play different roles in insulin-like growth factor I signaling. J Biol Chem 273:34543-34550, 1998
51. Vanhaesebroeck B, Higashi K, Raven C, Welham M, Anderson S, Brennan P, Ward SG, Waterfield MD: Autophosphorylation of p110δ phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO J 18:1292-1302, 1999
52. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzzo A, Giordano C, Trucco M: Nitric oxide primes pancreatic β-cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 186:1193-1200, 1997
53. Minshall C, Arkins S, Dantzer R, Freund GG, Kelley KW: Phosphatidylinositol 3′-kinase, but not S6-kinase, is required for IGF-I and IL-4 to maintain expression of Bcl-2 and promote survival of myeloid progenitors. J Immunol 162:4542-4549, 1999
54. Liu Q, Schacher D, Hurth C, Freund GG, Dantzer R, Kelley KW: Activation of phosphatidylinositol 3′-kinase by insulin-like growth factor-I rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes. J Immunol 159:820-837, 1997
55. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566, 1998